Clinical treatment with CSPG4-targeted 212Pb-RICs would be relevant for adjuvant settings after resection of the primary macroscopic tumor, or in treating early stages of recurrent or metastatic disease, when microscopic populations of malignant cells are present. Here, CSPG4 is linked to neoplasm.